Cardax, Inc.

Climate Impact & Sustainability Data (2014-09-30, 2016-06-30, 2017-03, 2019)

Recurring losses from operations raising substantial doubt about the Company’s ability to continue as a going concern.

Plans to raise additional capital through future equity and debt securities issuances.

Recurring losses from operations resulting in substantial doubt about the ability to continue as a going concern.
Negative cash flows from operating activities since inception.
Anticipation of further losses in the development of its business.

Plans to raise additional capital to carry out its business plan.
Furloughing of employees and independent contractors with minimum wage compensation for key personnel.
Deferred payment of trade payables.
Suspension of additional equity compensation for directors.
Assessment of commercial opportunities, including product development and licensing of intellectual property.

Recurring losses from operations since inception, resulting in an accumulated deficit and negative cash flows.
Substantial doubt about the ability to continue as a going concern.

Plans to raise additional capital through future equity and debt securities issuances.
Furloughing employees and contractors, reducing compensation for executives and directors, deferring payment of trade payables.
Focus on initial marketing program for ZanthoSyn™ to physicians, healthcare professionals, and consumers.

Short-term Goals:

Filing an IND for CDX-101 approximately one year from the closing of the Proposed Public Offering.

Recurring operating losses.
Substantial doubt about the Company’s ability to continue as a going concern.
Dependence on senior management and certain consultants.
Limited experience in managing communications with regulatory authorities.
Intense competition in the dietary supplement and pharmaceutical industries.
Extensive and complex healthcare regulation.
Limited experience as a commercial company.
Uncertainty regarding market acceptance of ZanthoSyn® and future products.
Limited experience in marketing products.
Reliance on third parties for supply and manufacturing.
Reliance on third-party distributors for sales, marketing, and distribution.
Potential for product liability claims and product recalls.
Fluctuation in operating results.
Challenges in managing expected growth.
Limited access to information regarding the Company due to smaller reporting company status.
Limited trading market for common stock.
Potential for penny stock regulations.
No dividend payments anticipated.
Potential issuance of preferred stock that could subordinate common stock rights.
Provisions in corporate charter documents that could make acquisition more difficult.
Potential for short sales to depress common stock price.
Derivative liabilities that may reduce stockholders' equity.
Potential adverse effects from natural disasters, public health crises, and other catastrophic events.
Potential adverse effects from pandemics, including COVID-19.

Raising additional capital.
Implementing business plan.
Hiring additional personnel or outsourcing functions.
Securing regulatory approvals.
Developing and commercializing new products.
Protecting intellectual property rights.
Establishing and maintaining sophisticated sales and marketing teams.
Improving existing and implementing new operational and financial systems.
Expanding, training, and managing employee base.
Utilizing contract manufacturers and suppliers.
Establishing and maintaining satisfactory relationships with third-party distributors.
Purchasing insurance coverage.
Managing expected growth effectively.
Filing a registration statement for a proposed $15 million public offering.